Barclays Maintains Overweight on AbbVie, Raises Price Target to $212
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on AbbVie and raises the price target from $200 to $212.
October 07, 2024 | 6:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Carter Gould has increased the price target for AbbVie from $200 to $212 while maintaining an Overweight rating. This suggests a positive outlook for AbbVie's stock.
The increase in price target from $200 to $212 by Barclays, along with the maintained Overweight rating, indicates a positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100